标题
Role of Vonoprazan in Helicobacter pylori Eradication Therapy in Japan
作者
关键词
-
出版物
Frontiers in Pharmacology
Volume 9, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2019-01-15
DOI
10.3389/fphar.2018.01560
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Vonoprazan, a Novel Potassium-Competitive Acid Blocker, Should Be Used for the Helicobacter pylori Eradication Therapy as First Choice: A Large Sample Study of Vonoprazan in Real World Compared with Our Randomized Control Trial Using Second-Generation Proton Pump Inhibitors for Helicobacter pylori Eradication Therapy
- (2018) Haruhiko Ozaki et al. DIGESTION
- Systematic review with meta-analysis: Vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori
- (2018) Min Li et al. HELICOBACTER
- Cost-effectiveness of a tailored Helicobacter pylori eradication strategy based on the presence of a 23S ribosomal RNA point mutation that causes clarithromycin resistance in Korean patients
- (2018) Jun-Hyung Cho et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Pre-treatment with proton pump inhibitors decreases the success of primary Helicobacter pylori eradication using a vonoprazan-based regimen
- (2018) Satoshi Shinozaki et al. KAOHSIUNG JOURNAL OF MEDICAL SCIENCES
- Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication
- (2018) Hiroki Tanabe et al. Annals of Clinical Microbiology and Antimicrobials
- Randomized trial of vonoprazan-based versus proton-pump inhibitor-based third-line triple therapy with sitafloxacin for Helicobacter pylori
- (2018) Soichiro Sue et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Vonoprazan improves the efficacy of Helicobacter pylori eradication therapy with a regimen consisting of clarithromycin and metronidazole in patients allergic to penicillin
- (2017) Shoko Ono et al. HELICOBACTER
- Vonoprazan- vs proton-pump inhibitor-based first-line 7-day triple therapy for clarithromycin-susceptible Helicobacter pylori : A multicenter, prospective, randomized trial
- (2017) Soichiro Sue et al. HELICOBACTER
- Review: A Japanese population-based meta-analysis of vonoprazan versus PPI for Helicobacter pylori eradication therapy: Is superiority an illusion?
- (2017) Shou Quan Dong et al. HELICOBACTER
- The Superiority of Vonoprazan-based First-line Triple Therapy with Clarithromycin: A Prospective Multi-center Cohort Study on Helicobacter pylori Eradication
- (2017) Soichiro Sue et al. INTERNAL MEDICINE
- Effects of patient age and choice of antisecretory agent on success of eradication therapy for Helicobacter pylori infection
- (2017) Toshihiro Nishizawa et al. JOURNAL OF CLINICAL BIOCHEMISTRY AND NUTRITION
- Comparative study: Vonoprazan and proton pump inhibitors in Helicobacter pylori eradication therapy
- (2017) Kouichi Sakurai et al. WORLD JOURNAL OF GASTROENTEROLOGY
- First-Line Helicobacter pylori Eradication with Vonoprazan, Clarithromycin, and Metronidazole in Patients Allergic to Penicillin
- (2017) Soichiro Sue et al. Gastroenterology Research and Practice
- Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-LineHelicobacter pyloriEradication: A Randomized Controlled Trial
- (2017) Masafumi Maruyama et al. Canadian Journal of Gastroenterology and Hepatology
- Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype
- (2016) T. Kagami et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- The Efficacy and Tolerability of a Triple Therapy Containing a Potassium-Competitive Acid Blocker Compared With a 7-Day PPI-Based Low-Dose Clarithromycin Triple Therapy
- (2016) Sho Suzuki et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- A Comparative Study of a New Class of Gastric Acid Suppressant Agent Named Vonoparazan versus Esomeprazole for the Eradication of Helicobacter pylori
- (2016) Masahiro Tsujimae et al. DIGESTION
- Helicobacter pylori Eradication with Proton Pump Inhibitors or Potassium-Competitive Acid Blockers: The Effect of Clarithromycin Resistance
- (2016) Hiroshi Matsumoto et al. DIGESTIVE DISEASES AND SCIENCES
- Efficacy of vonoprazan-based second-line Helicobacter pylori eradication therapy in patients for whom vonoprazan-based first-line treatment failed
- (2016) Yasumi Katayama et al. GUT
- Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy forHelicobacter pylorieradication: a phase III, randomised, double-blind study
- (2016) Kazunari Murakami et al. GUT
- Management ofHelicobacter pyloriinfection—the Maastricht V/Florence Consensus Report
- (2016) P Malfertheiner et al. GUT
- High antibiotic resistance ofHelicobacter pyloriand its effect on tailored and empiric eradication of the organism in Lower Silesia, Poland
- (2016) Stanisław Ferenc et al. HELICOBACTER
- Vonoprazanversusconventional proton pump inhibitor-based triple therapy as first-line treatment againstHelicobacter pylori: A multicenter retrospective study in clinical practice
- (2016) Satoki Shichijo et al. Journal of Digestive Diseases
- A novel potassium-competitive acid blocker improves the efficacy of clarithromycin-containing 7-day triple therapy against Helicobacter pylori
- (2016) Journal of Gastrointestinal and Liver Diseases
- Comparison of vonoprazan and proton pump inhibitors for eradication of Helicobacter pylori
- (2016) Satoshi Shinozaki et al. KAOHSIUNG JOURNAL OF MEDICAL SCIENCES
- Analysis of the cost-effectiveness of using vonoprazan–amoxicillin–clarithromycin triple therapy for first-line Helicobacter pylori eradication
- (2016) Yusaku Kajihara et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- In vitro metabolism of TAK-438, vonoprazan fumarate, a novel potassium-competitive acid blocker
- (2016) Hitomi Yamasaki et al. XENOBIOTICA
- HighHelicobacter pyloricure rate with sitafloxacin-based triple therapy
- (2015) M. Sugimoto et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- The binding selectivity of vonoprazan (TAK-438) to the gastric H+,K+-ATPase
- (2015) D. R. Scott et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects
- (2015) H. Jenkins et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Letter: promising results ofHelicobacter pylorieradication with vonoprazan-based triple therapy after failure of proton pump inhibitor-based triple therapy
- (2015) T. Inaba et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects - a randomised open-label cross-over study
- (2015) Y. Sakurai et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Efficacy of 10-day Sitafloxacin-Containing Third-Line Rescue Therapies forHelicobacter pyloriStrains Containing thegyrAMutation
- (2015) Hideki Mori et al. HELICOBACTER
- Efficacy of TailoredHelicobacter pyloriEradication Treatment Based on Clarithromycin Susceptibility and Maintenance of Acid Secretion
- (2014) Mitsushige Sugimoto et al. HELICOBACTER
- Eradication of H. pylori Infection in Patients Allergic to Penicillin Using Triple Therapy with a PPI, Metronidazole and Sitafloxacin
- (2014) Takahisa Furuta et al. INTERNAL MEDICINE
- Multi-center randomized controlled study to establish the standard third-line regimen for Helicobacter pylori eradication in Japan
- (2013) Kazunari Murakami et al. JOURNAL OF GASTROENTEROLOGY
- Sitafloxacin-based third-line rescue regimens forHelicobacter pyloriinfection in Japan
- (2013) Takahisa Furuta et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Rabeprazole 10 mg q.d.s. decreases 24-h intragastric acidity significantly more than rabeprazole 20 mg b.d. or 40 mg o.m., overcoming CYP2C19 genotype
- (2012) M. Sugimoto et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Sitafloxacin resistance in Helicobacter pylori isolates and sitafloxacin-based triple therapy as a third-line regimen in Japan
- (2012) Yoshihiro Hirata et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Association of Helicobacter pylori dupA With the Failure of Primary Eradication
- (2012) Seiji Shiota et al. JOURNAL OF CLINICAL GASTROENTEROLOGY
- Efficacy of Sitafloxacin-Based Rescue Therapy for Helicobacter pylori after Failures of First- and Second-Line Therapies
- (2011) Juntaro Matsuzaki et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Impact of Acid Inhibition on Esophageal Mucosal Injury Induced by Low-Dose Aspirin
- (2011) Mitsushige Sugimoto et al. DIGESTION
- Role of Omeprazole Dosage and Cytochrome P450 2C19 Genotype in Patients Receiving Omeprazole-Amoxicillin Dual Therapy forHelicobacter pyloriEradication
- (2011) Jyh-Chin Yang et al. PHARMACOTHERAPY
- Sitafloxacin and Garenoxacin May Overcome the Antibiotic Resistance of Helicobacter pylori with gyrA Mutation
- (2009) H. Suzuki et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Sitafloxacin Activity against Helicobacter pylori Isolates, Including Those with gyrA Mutations
- (2009) K. Murakami et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Virulence factor genotypes of Helicobacter pylori affect cure rates of eradication therapy
- (2009) Mitsushige Sugimoto et al. ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS
- Helicobacter pylori first-line treatment and rescue option containing levofloxacin in patients allergic to penicillin
- (2009) J.P. Gisbert et al. DIGESTIVE AND LIVER DISEASE
- Effect of MDR1 C3435T polymorphism on lansoprazole in healthy Japanese subjects
- (2009) Chise Kodaira et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Tailored eradication therapy based on fecalHelicobacter pyloriclarithromycin sensitivities
- (2008) Takashi Kawai et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now